News Daily News FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes Shelley Wood December 02, 2016
News Daily News FDA Approval of Cangrelor Expands Antiplatelet Options for PCI Todd Neale June 29, 2015
News Daily News Un Panel de la FDA Rechaza el Cangrelor para las Indicaciones PCI y Terapia Puente Yael L. Maxwell February 13, 2014
News Daily News FDA Panel Rejects Cangrelor for Both PCI, Bridging Indications Yael L. Maxwell February 13, 2014
News Industry News FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome May 23, 2012
News Industry News FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation September 08, 2011